eSights' new assistive technology helps patients with central vision loss

Video

Roland Mattern, director of marketing for eSight, illustrates the use of the company's eSight 4 device to assist patients with central vision loss.

Roland Mattern, director of marketing for eSight, sat down with Optometry Times during the 2022 American Academy of Optometry meeting held in San Diego to give a demonstration of the company's eSight 4 device, an assistive technology for patients with central vision loss.

Editor's note: This transcript has been edited for clarity.

Hi there, I'm Roland Mattern, and I'm the director of marketing for eSight. This is our device, eSight 4. It is an assistive technology for patients with central vision loss. The way it works is, the camera picks up the image that the person can no longer perceive, runs it through a software algorithm, and projects it onto two OLED monitors, one in front of each eye. And the wearer then uses a peripheral and parafoveal vision to process the visual stimuli.

The way it works is the way you wear it. It can be used for any activity of daily living, from reading to watching movies, to walking about or shopping or traveling. If I'm using it for reading or computer work, I'd wear it like this, in a fully down position, but if I want to ambulate, I can slightly tilt it up. Now my peripheral vision is completely unobstructed, and I can walk around using my peripheral vision. If I approached somebody, a street sign, a food label, a price tag, an Uber, I can always point the camera momentarily at what I want to see, glance up, and I can read what is in front of me. So it's a very versatile technology.

We are aimed at patients with visual acuity of about 20/80 to 20/100. And in many cases, we'll get people back down to 20/20 vision, functional vision.

We are completely validated with a clinical study, where we have demonstrated seven line distance acuity gain, a 12 letter contrast gain, significant improvement in facical recognition, which of course it's very important to the human aspect of the technology. And we also have 100% mobility, which is unique for our product, whereas many products that are VR-based completely block your peripheral vision; now that aspect of mobility is lost.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.